Historical Perspectives in Critical Care Medicine: Blood Transfusion, Intravenous Fluids, Inotropes/Vasopressors, and Antibiotics

Critical Care Clinics

Volumn 25, Issue 1, 2009, Pages 201-220

  Zarychanski, Ryan ^a   Ariano, Robert E ^b   Paunovic, Bojan ^a   Bell, Dean D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anti bacterial agents; Blood transfusion; Critical care; History of medicine; Infusions; Intravenous; Vasoconstrictor agents

Indexed keywords

ADRENALIN; AMRINONE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BICARBONATE; CEPHALOSPORIN; DOBUTAMINE; DOMPERIDONE; EMETIC AGENT; EPHEDRINE; HYPERTENSIVE AGENT; INFUSION FLUID; INOTROPIC AGENT; ISOPRENALINE; MEPHENTERMINE; METARAMINOL; METHOXAMINE; MILRINONE; NORADRENALIN; OXEDRINE; PHENYLEPHRINE; POLYPEPTIDE ANTIBIOTIC AGENT; POVIDONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; SODIUM CHLORIDE; SULFONAMIDE; UNINDEXED DRUG; VANCOMYCIN; VASOPRESSIN;

ADRENERGIC ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ASTHMA; BACTEREMIA; BLEEDING; BLOOD CONSERVATION; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CHOLERA; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; COLLOID; CRITICAL ILLNESS; DEHYDRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROCOCCAL INFECTION; ERYTHROCYTE PRESERVATION; FLUID RESUSCITATION; FLUID THERAPY; FUTUROLOGY; HEMOLYSIS; HEMOPHILIA; HISTORY OF MEDICINE; HUMAN; HYPOTENSION; INFECTION COMPLICATION; INFECTION RISK; INJURY; INTENSIVE CARE; MEDICAL RESEARCH; MENTAL DISEASE; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SEIZURE; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; WAR;

ABO BLOOD-GROUP SYSTEM; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD TRANSFUSION; CARBAPENEMS; CARDIOTONIC AGENTS; CEPHALOSPORINS; CRITICAL CARE; EUROPE; FLUID THERAPY; FLUOROQUINOLONES; GLYCOPEPTIDES; HISTORY, 16TH CENTURY; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; INFUSIONS, INTRAVENOUS; ISOTONIC SOLUTIONS; JAPAN; LIPOPEPTIDES; MILITARY MEDICINE; OXAZOLIDINONES; UNITED STATES; VASOCONSTRICTOR AGENTS;

EID: 61549131653     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2008.10.003     Document Type: Review

References (118)

1. Giangrande P.L. The history of blood transfusion. Br J Haematol 110 (2000) 758-767
2. Corwin H.L., Gettinger A., Pearl R.G., et al. The CRIT study: anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med 32 (2004) 39-52
3. Rodriguez R.M., Corwin H.L., Gettinger A., et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 16 (2001) 36-41
4. Wise M.W., and Oleary J.P. The origins of blood transfusion: early history. Am Surg 68 (2002) 98-100
5. Rivera A.M., Strauss K.W., van Z.A., et al. The history of peripheral intravenous catheters: how little plastic tubes revolutionized medicine. Acta Anaesthesiol Belg 56 (2005) 271-282
6. Pelis K. Taking credit: the Canadian Army Medical Corps and the British conversion to blood transfusion in WWI. J Hist Med Allied Sci 56 (2001) 238-277
7. Rous P., and Turner J.R. Preservation of living red blood corpuscles in vitro. II. The transfusion of kept cells. J Exp Med 23 (1916) 239-248
8. Robertson L.B. The transfusion of whole blood. A suggestion for its more frequent employment in war surgery. Br Med J 2 (1916) 38-40
9. Pinkerton P.H. Canadian surgeons and the introduction of blood transfusion in war surgery. Transfus Med Rev 22 (2008) 77-86
10. Hess J.R., and Thomas M.J. Blood use in war and disaster: lessons from the past century. Transfusion 43 (2003) 1622-1633
11. Cohn E.J., Oncley J.L., Strong L.E., et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation I: the characterization of the protein fractions of human plasma. J Clin Invest 23 (1944) 417-432
12. Starr D. Medicine, money, and myth: an epic history of blood. Transfus Med 11 (2001) 119-121
13. Yazer M.H., Podlosky L., Clarke G., et al. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 44 (2004) 10-15
14. Blumberg N., Zhao H., Wang H., et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 47 (2007) 573-581
15. Tinmouth A.T., McIntyre L.A., and Fowler R.A. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. CMAJ 178 (2008) 49-57
16. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (1999) 409-417
17. Natanson C., Kern S.J., Lurie P., et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299 (2008) 2304-2312
18. Zarychanski R., Turgeon A.F., McIntyre L., et al. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 177 (2007) 725-734
19. Borgman M.A., Spinella P.C., Perkins J.G., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63 (2007) 805-813
20. Ketchum L., Hess J.R., and Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 60 (2006) S51-S58
21. Malone D.L., Hess J.R., and Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma 60 (2006) S91-S96
22. Lewins R. Injection of saline solutions in extraordinary quantities into the veins in cases of malignant cholera. Lancet 2 (1832) 243-244
23. Howard-Jones N. Cholera therapy in the nineteenth century. J Hist Med Allied Sci 27 (1972) 373-395
24. O'Shaughnessy W. Proposal of a new method of treating the blue epidemic cholera by the injection of highly-oxygenated salts into the venous system. Lancet 17 (1831) 366-371
25. O'Shaughnessy W. Report on the chemical pathology of the blood in cholera, published by authority of the Central Board of Health. Lancet 17 (1832) 929-936
26. Awad S., Allison S., and Lobo D. The history of 0.9% saline. Clin Nutr 27 (2008) 179-188
27. Latta T. Documents communicated by the Central Board of Health, London, relative to the treatment of cholera by the copious injection of aqueous and saline fluids into the veins. Lancet 18 (1832) 274-277
28. Finberg L. The early history of the treatment for dehydration. Arch Pediatr Adolesc Med 152 (1998) 71-73
29. Cosnett J.E. The origins of intravenous fluid therapy. Lancet 1 (1989) 768-771
30. Jennings C. The intravenous injection of fluid for severe haemorrhage: part I. Lancet 120 (1882) 436-437
31. Thelwall T. Injection of saline solution in shock. Lancet 152 (1898) 1390-1391
32. Lee J.A. Sydney Ringer (1834-1910) and Alexis Hartmann (1898-1964). Anaesthesia 36 (1981) 1115-1121
33. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the ventricle. J Physiol 4 (1883) 29-42
34. Barsoum N., and Kleeman C. Now and then, the history of parenteral fluid administration. Am J Nephrol 22 (2002) 284-289
35. Dudrick S.J. History of vascular access. JPEN J Parenter Enteral Nutr 30 (2006) S47-S56
36. Landerer A. Ueber transfusion und infusion. Verhandl Dtsch Ges Chir 15 (1886) 280-282 [in German]
37. Matas R. A clinical report on intravenous saline infusion in the wards of the New Orleans Charity Hospital from June 1888, to June 1891. New Orleans Med Surg J 19 (1891) 1-93
38. Rogers L. The mortality from post-choleraic uraemia: a 70 per cent reduction though intravenous injections of sodium bicarbonate. Lancet 2 (1917) 745-746
39. Sellards A. Tolerance for alkalies in asiatic cholera. Philippine J Sci 5 (1910) 363-389
40. Cannon W., John F., and Cowell E. The preventive treatment of wound shock. JAMA 70 (1918) 618-621
41. Bayliss W. Methods of raising a low arterial pressure. Proc R Soc Med 89 (1916) 380-393
42. Saddler J.M., and Horsey P.J. The new generation gelatins. A review of their history, manufacture and properties. Anaesthesia 42 (1987) 998-1004
43. Macintosh J. Principles of pathology and practice of physic vol. 1 (1837), Edward C Biddle, Philadelphia
44. Hassig A., and Stampfli K. Plasma substitutes past and present. Bibl Haematol 33 (1969) 1-8
45. Cohn E.J. Blood proteins and their therapeutic value. Science 101 (1945) 51-56
46. Evidence-based colloid use in the critically ill: American Thoracic Society consensus statement. Am J Respir Crit Care Med 170 (2004) 1247-1259
47. Gamble J., Ross G., and Tisdall F.F. The metabolism of fixed base during fasting. J Biol Chem 57 (1923) 633-695
48. Coller F., Campbell K., Vaughan H., et al. Postoperative salt intolerance. Ann Surg 119 (1944) 533-541
49. Moore F. Metabolic care of the surgical patient (1959), WB Saunders, Philadelphia
50. Shires T., Coln D., Carrico J., et al. Fluid therapy in hemorrhagic shock. Arch Surg 88 (1964) 688-693
51. Jenkins M.T. History of sequestered edema associated with surgical operations and trauma. Contemp Anesth Pract 6 (1983) 1-31
52. Roth E., Lax L., and Maloney J.V. Ringer's lactate solution and extracellular fluid volume in the surgical patient: a critical analysis. Ann Surg 169 (1969) 149-164
53. Moore F., and Shires G. Moderation. Ann Surg 166 (1967) 300-301
54. Brandstrup B., Svensen C., and Engquist A. Hemorrhage and operation cause a contraction of the extracellular space needing replacement-evidence and implications? A systematic review. Surgery 139 (2006) 419-432
55. Shires G. Re: hemorrhage and operation cause a contraction of the extracellular space needing replacement-evidence and implications? A systematic review. Surgery 141 (2007) 544
56. Alam H.B., and Rhee P. New developments in fluid resuscitation. Surg Clin North Am 87 (2007) 55-72
57. Kreimeier U., and Prueckner S. Small-volume resuscitation from hemorrhagic shock by hypertonic saline dextran-conceptional basis and historical background. Eur Surg Res 34 (2002) 138-144
58. Stewart P.A. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol 61 (1983) 1444-1461
59. Shoemaker W.C. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94 (1988) 1176-1186
60. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377
61. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 317 (1998) 235-240
62. Finfer S., Bellomo R., Boyce N., et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004) 2247-2256
63. Myburgh J., Cooper D.J., Finfer S., et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357 (2007) 874-884
64. Brunkhorst F.M., Engel C., Bloos F., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358 (2008) 125-139
65. Bancroft H., and Talbot J.F. Oliver and Schafer's discovery of the cardiovascular action of suprarenal extract. Postgrad Med J 44 (1968) 6-8
66. Oliver G., and Schafer E.A. The physiologic effects of extracts of the suprarenal capsules. J Physiol 18 (1895) 230-276
67. Sneader W. Drug discovery-a history (2005), John Wiley & Sons Ltd, Chichester, West Sussex (UK)
68. Abel J.J. On epinephrine, the active constituent of the suprarenal capsule and its compounds. Proc Am Physiol Soc 16 (1898) 3-5
69. Aronson J.K. Where name and image meet-the argument for adrenaline. BMJ 320 (2000) 506-509
70. Yasmashima T. Jokichi Takamine (1854-1922), the samurai chemist, and his work on adrenalin. J Med Biogr 11 (2003) 95-102
71. Takamine J. Adrenalin: the active principle of the suprarenal gland. Am J Pharm 73 (1901) 523-531
72. Davenport H.W. Epinephrin(e). Physiologist 25 (1982) 76-82
73. Elliot T.R. The action of adrenalin. J Physiol 32 (1905) 401-467
74. Elliot T.R. The action of adrenalin. J Physiol 31 (1904) 20-21
75. Barger G., and Dale H.H. Chemical structure and sympathathomimetic action of amines. J Physiol 41 (1910) 19-59
76. Nathanson M.H., and Miller H. The action of norepinephrine, epinephrine and isopropyl norepinephrine on the rhythmic function of the heart. Circulation 6 (1952) 238-244
77. Eichna L.W. The treatment of cardiogenic shock III. The use of isoproterenol in cardiogenic shock. Am Heart J 74 (1967) 48-52
78. Tuttle R.R., and Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36 (1975) 185-196
79. Bennett M.R. One hundred years of adrenaline: the discovery of autoreceptors. Clin Auton Res 9 (1999) 145-159
80. Goldenberg M., Apgar V., Deterling R., et al. Nor-epinephrine (arterenol, sympathin N) as a pressor drug. JAMA 140 (1949) 776-778
81. Livesay W.R., and Chapman D.W. The treatment of acute hypotensive states with l-norepinephrine. Am J Med Sci 225 (1953) 159-171
82. Goldberg L.I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24 (1972) 1-29
83. MacCannell K.L., McNay J.L., Meyer M.B., et al. Dopamine in the treatment of hypotension and shock. N Engl J Med 275 (1966) 1389-1398
84. Loeb H.S., Winslow E.B., Rahimtoola S.H., et al. Acute hemodynamic effects of dopamine in patients with shock. Circulation 44 (1971) 163-173
85. Marik P.E. Low-dose dopamine: a systematic review. Intensive Care Med 28 (2002) 877-883
86. Ahlquist R.P. A study of the adrenotropic receptors. Am J Phys 153 (1948) 586-600
87. Bylund D.B. Alpha- and beta-adrenergic receptors: Ahlquist's landmark hypothesis of a single mediator with two receptors. Am J Physiol Endocrinol Metab 293 (2007) E1479-E1481
88. Aviado Jr. D.M. Cardiovascular effects of some commonly used pressor amines. Anesthesiology 20 (1959) 71-97
89. Fankhauser A., Fishman S.I., Madonia P.F., et al. The use of aramine in clinical shock. Circulation 13 (1956) 834-836
90. Weil M.H. Current concepts on the management of shock. Circulation 16 (1957) 1097-1105
91. Smith N.T., and Corbascio A.N. The use and misuse of pressor agents. Anesthesiology 33 (1970) 58-101
92. Zaimis E. Vasopressor drugs and catecholamines. Anesthesiology 29 (1968) 732-762
93. Oliver H., and Schafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol 18 (1895) 277-279
94. Light G.A., Rattenborg C., and Holaday D.A. A new vasoconstrictor: preliminary studies of phelypressin. Anesth Analg 44 (1965) 280-287
95. Russell J.A., Walley K.R., Singer J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 (2008) 877-887
96. Farah A.E. Historical perspectives on inotropic agents. Circulation 73 (1986) III4-III9
97. Alousi A.A., and Johnson D.C. Pharmacology of the bipyridines: amrinone and milrinone. Circulation 73 (1986) III10-III24
98. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296-327
99. Khardori N. Antibiotics-past, present, and future. Med Clin North Am 90 (2006) 1049-1076
100. Stewart WH. A Mandate for State Action; presented at the Association of State and Territorial Health Officers, Washington, D.C., Dec 4, 1967. Taken from: Garrett L. The Coming Plague: Newly Emerging Diseases in a World Out of Balance. New York: Penguin Books; 1994. p. 33.
101. Mandell G.L., and Sande M.A. Antimicrobial agents-the cephalosporins. In: Goodman A., and Gillman A.G. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 7 edition (1985), Macmillan, New York
102. Marshall W.F., and Blair J.E. The cephalosporins. Mayo Clin Proc 74 (1999) 187-195
103. Chow J.W., Fine M.J., Shlaes D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115 (1991) 585-590
104. Drusano G.L. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 27 Suppl 1 (1998) S111-S116
105. Levine D.P. Vancomycin: a history. Clin Infect Dis 42 Suppl 1 (2006) S5-S12
106. Aksoy D.Y., and Unal S. New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clin Microbiol Infect 14 (2008) 411-420
107. Spratt B.G., Jobanputra V., and Zimmermann W. Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12. Antimicrobial Agents Chemother 12 (1977) 406-409
108. Hellinger W.C., and Brewer N.S. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 74 (1999) 420-434
109. Norrby S.R., Alestig K., Ferber F., et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrobial Agents Chemother 23 (1983) 293-299
110. Shadomy S., and May R.S. N-formimidoyl thienamycin (MK0787): in vitro study. Antimicrobial Agents Chemother 19 (1981) 201-204
111. Walker R.C. The fluoroquinolones. Mayo Clin Proc 74 (1999) 1030-1037
112. Fernandes P. Antibacterial discovery and development-the failure of success?. Nat Biotechnol 24 (2006) 1497-1503
113. Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45 (2007) 3352-3359
114. Zhanel G.G., Shroeder C., Vercaigne L., et al. A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?. Can J Infect Dis 12 (2001) 379-390
115. Huang V., and Gortney J.S. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 26 (2006) 1784-1793
116. Schriever C.A., Fernandez C., Rodvold K.A., et al. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62 (2005) 1145-1158
117. Sauermann R., Rothenburger M., Graninger W., et al. Daptomycin: a review 4 years after first approval. Pharmacology 81 (2008) 79-91
118. Fergusson D.A., Hébert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 22 (2008) 2319-2331